Lilly's Growth in Diabetes and Obesity, and Strong Oncology and Immunology Drugs Create a Wide Moat
Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...
Insider Monkey14d
10 Most Promising Dividend Stocks According to Hedge Funds
Currently, there are two phase-three assets: orforglipron, an oral GLP-1, and retatrutide ... strong earnings and an efficient capital structure. UnitedHealth Group Incorporated (NYSE:UNH ...
NBC Washington9d
Eli Lilly to release late-stage data on next-generation weight loss drug retatrutide in 2025, earlier than expected
Eli Lilly said it expects to release data from a late-stage trial on its next-generation weight loss drug retatrutide in 2025, a few months earlier than expected. The company expects to provide ...
Nature9d
The weight-loss drugs being tested in 2025: will they beat Ozempic?
In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...
Business Insider20d
Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot
"Not all GLP-1s are the same." Retatrutide, the 'King Kong' drug to mimic bariatric surgery Eli Lilly isn't pivoting away from weekly weight loss injections entirely. It's also working on another ...